Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
now .16 !!!!!!!
we break the .15 !!!!!!!
10K this week ?
all ready ?
cb
no selling @ this level ...
hm
cb
10Q filing in few days !!!!!!!! 10 days up trend
cb
another good news in the pipeline, the weekend was very good
super mail for me and actc ......
cb
wednesday between .26 and .29
imho
good luck
cb
i see a up-trend monday and next week. good luck
cb
in, thanks
cb
my first buy order in at .160
cb
Congratulation to a new uptrend with ACTC
surprise for me
cb
ACTC is in play >>>respect.
cb
Congratutation !
cb
sell when you can !!!!!!!!! stem cell´s going down
stop the short !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
cb
ACTC up-trend
cb
I see, ACTC will going up ...
nice
cb
.13 today
cb
News after the bell today?
cb
The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928.
The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY).
Below is a profile for each company, including a summary of their business and research focus along with website links, beginning with Cord Blood America (CBAI.OB), which leads the index in terms of year-to-date stock price appreciation, registering a gain of 279.2% for the year. CBAI recently announced a successful debt restructuring and projected cash flow positive results by mid-year.
Cord Blood America preserves umbilical cord blood stem cells through a quick and non-invasive procedure at the time of birth. CBAI is focused on marketing initiatives to increase awareness of their services, which literally represent a once in a lifetime opportunity to collect and preserve cord blood stem cells which can be used in the future to treat dozens of conditions with the promise of even more medical breakthroughs with the FDA ruling to allow human stem cell testing and pending federal funding for stem cell research.
ReNeuron Group PLC (UK: RENE.L) (RNUGF.PK) is a UK-based adult stem cell company which will be conducting clinical studies with lead stem cell therapy candidate (ReN001) for disabled stroke patients. The Company also offers a range of stem cell lines for non-therapeutic applications, including ReNcell products for use in academic and commercial research. The ReNcellCX and ReNcellVM neural cell lines are marketed globally by Millipore (MIL).
Integra LifeSciences (IART) is a medical instrument and surgical implant company with regenerative medicine operations that focus on orthopaedic (bone grafts + regeneration) and dermal (skin regeneration + wound care) applications.
Osiris Therapeutics (OSIR) is an adult stem cell company which is developing product candidates derived from bone marrow. Prochymal is being evaluated in Phase 3 clinical trials for Graft versus Host Disease (GvHD) + Crohn's disease and in earlier stage trials for diabetes and heart attack. Chondrogen is being evaluated in a Phase 1/2 clinical trial for pain/arthritis of the knee.
Geron (GERN) is a human embryonic stem cell (hESC) company which received FDA approval in January 2009 to begin human testing in a Phase 1 clinical trial of GRNOPC1 for the treatment of acute spinal cord injuries.
Orthovita (VITA) develops bio-materials and medical instruments for orthopaedic and spinal surgery applications. The Company offers Vitoss as a synthetic bone graft for injury repair; Vitagel to control bleeding during surgery (derived from a patient's own plasma combined with collagen and thrombin); Imbibe is a family of disposable equipment used to harvest regenerative cells from a patient's bone marrow and to deliver bone grafts; and Cortoss is being evaluated in clinical trials in the U.S. as a bone augmentation bio-material.
Kensey Nash (KNSY) is a medical device maker which is focused on cardiovascular products and bio-materials for orthopaedic applications, including a partnership with Orthovita (VITA) for combinations with the Vitoss bone graft.
SurModics (SRDX) is a drug delivery specialist with a regenerative medicine division that focuses on applications for tissue/organ repair in addition to other business units for orthopedic repair and diagnostics.
ReGen Biologics (RGBO.OB) is a regenerative medicine company which develops products for tissue growth and repair, with a focus on orthopedic applications such as it flagship product - the Menaflex collagen meniscus biologically-derived implant.
Alseres Pharma (ALSE) is a regenerative medicine company focused on developing new treatments for spinal cord injuries (Cethrin - a recombinant protein) and a new molecular imaging diagnostic agent (Altropane) to differentiate Parkinson's disease from other types of tremors.
CryoLife (CRY) has progressed from its initial focus on cold temperature preservation of tissue-based cardiovascular implants to the development of implantable bio-derived medical devices, surgical adhesives, and other bio-materials used in surgical applications.
Stem Cell Authority (SCAL.PK) provides cell banking and preservation services for a newborn's Mirachymal (mesenchymal - develop into muscle, bone, and other connective tissues) and Hematopoietic (develop into blood cells and components) stem cells, derived from inside the umbilical cord and within the cord blood.
Stem Cell Therapy International (SCII.OB) is a regenerative medicine company which focuses on stem cell transplants and biological solutions.
EpiStem (UK: EHP.L) is an epithelial stem cell company focused on gastrointestinal disorders, oncology, and dermatology applications. The Company also provides preclinical contract research services and is not involved with embryonic stem cells or stem cell transplants.
StemCells (STEM) engages in clinical and preclinical research and development for human neural stem cells and liver engrafting cells. Earlier stage preclinical work is focused on spinal cord injuries, myelin, and retinal disorders.
BioMimetic Therapeutics (BMTI) develops regenerative medicine device/therapeutic combination products for bio-therapeutic applications for orthopedic/spine, sports medicine, and dental procedures.
RTI Biologics (RTIX) is a provider of bio-implants and grafts to promote healing and repair for orthopedic/spinal applications, sports medicine, bone graft substitutes, and cardiovascular applications.
Cytori Therapeutics (CYTX) is a commercial-stage regenerative medicine company which is developing the Celution System to process a patient's own fat (adipose) tissue in about one hour for a variety of reconstructive and cosmetic medicine therapeutic applications.
CYTX also offers StemSource Cell Banking for a patient to preserve their own adipose-derived stem + regenerative cells (ADRCs) for use in the future as ongoing clinical trials establish the safety and effectiveness for cardiovascular disease, breast reconstruction/augmentation, liver disease, kidney failure, orthopedic/spinal disc regeneration, and gastrointestinal disorders.
CYTX currently offers its products and services in Japan and Europe along with two key strategic partners - Olympus Corp. (OCPNY.PK) (a strategic investor + medical device partner for Celution System) and Green Hospital Supply (GHSPF.PK) (a strategic investor + partner for StemSource Cell Banking, initially targeting hospitals in Japan).
Aastrom Biosciences (ASTM) is developing autologous (derived from the patient) cell products for the repair and regeneration of human tissue. Aastrom's Tissue Repair Cell (TRC) technology utilizes a patient's own bone marrow as the source of progenitor and stem cells for use in cardiac and vascular tissue regeneration.
Mesoblast (MBLTY.PK) (Australia: MSB.AX) is an adult stem cell company focused on commercializing RepliCart for bone and cartilage repair and regeneration, with recent approval to conduct a Phase 2 clinical trial for knee osteoarthritis. Mesoblast also has a U.S. subsidiary focused on cardiovascular applications for its regenerative medicine technology.
BioTime (BTIM.OB) offers blood plasma expanders such as Hextend along with its Embryome Sciences subsidiary, which includes 11 new cell lines that will be marketed to universities and bio-pharma companies for use in research programs focused on developing new cell-based therapies for neurodegenerative disease, muscular dystrophy, heart disease, cancer, and arthritis, as well as other potential applications in the emerging field of regenerative medicine.
Osteotech (OSTE) provides OsteoBiologic solutions for regenerative medicine applications to repair and replace bone loss caused by trauma or disease, augment prosthetic implant procedures, facilitate spinal fusion, and replace/repair damaged ligaments and tendons.
Neuralstem (CUR) manufactures human neural stem cells for research grant and collaborative programs and outsources the manufacturing and storage of its stem cells for use in pre-clinical studies to Charles River Labs (CRL).
RegeneRx Biopharma (RGN) has developed three drug product candidates based on a peptide molecule (Thymosin beta 4), which demonstrates promise for a variety of tissue and organ repair applications. RGN-137 is a topical gel product for healing chronic dermal wounds. RGN-259 is an eye drop for ophthalmic injuries. RGN-352 is an injectable treatment for heart attacks.
ThermoGenesis (KOOL) is a commercial-stage provider of systems for the storage and processing of adult stem cells derived from cord blood and bone marrow. KOOL offers the AutoXpress Platform (AXP) (cord blood processing) as a family of automated devices which includes the MarrowXpress (bone marrow processing) and related disposables as a closed system to process and collect adult stem cells.
The CryoSeal FS System produces fibrin sealants from blood in about one hour for use in liver resection surgeries. KOOL also expects to enter the veterinary stem cell market under the Vantus brand and plans to launch Res-Q (a system for real-time processing of bone marrow and platelet rich plasma processing) during its fiscal 4Q09 as the Company hopes to achieve profitability during 2010.
Athersys (ATHX) collaborates with Angiotech Pharma (ANPI) to develop MultiStem for the treatment of damage caused by heart attacks, peripheral vascular disease, and strokes in addition to support for stem cell transplants.
Advanced Cell Technology (ACTC.PK) focuses on human embryonic and adult stem cell technology, with FDA approval to begin Phase 2 clinical trials for adult stem cell technologies, which are focused on cardiovascular disease and transplants.
International Stem Cell Corp (ISCO.OB) offers a unique technology technology, Parthenogenesis, which results in the creation of pluripotent (ability to differentiate into a variety of unique cell types) human stem cell lines from unfertilized human eggs. ISCO's technology has the potential to eliminate the rejection of stem cell transplants, avoid ethical issues by eliminating the need for fertilized embryos, and produce specialized cells for research applications.
Bioheart (BHRT.PK) recently secured private financing commitments for up to $7M and recently announced a grant-funded study in Italy for the Bioheart A&C Bio Science Twin-Pulsatile Life Support System which is expected to be completed within just 45 days with the potential for $2.1M in contract sales if results are positive.
BHRT develops devices and biological therapeutics for the diagnosis, treatment, and monitoring of cardiovascular disease and heart failure. MyoCell is the Company's lead product candidate, which represents a muscle-derived stem cell therapy designed to improve heart function by replacing scar tissue with living cells to restore function.
Pluristem Therapeutics (PSTI) has developed a pipeline of product candidates derived from the human placenta and processed by the Company's PluriX bio-reactor as allogeneic (ready-to-use, non-personalized cell therapy products). The Company's pipeline includes product candidates for the treatement of peripheral artery disease (PLX-PAD), inflammatory bowel disease (PLX-IBD), multiple sclerosis (PLX-MS), bone marrow transplants (PLX-BMT), and ischemic stroke (PLX-STROKE).
HepaLife Technologies (HPLF.OB) cell-based technologies under development include an artificial liver device (HepaMate), in-vitro toxicology and pre-clinical drug testing platforms, and cell-culture based vaccine production methods for the manufacture of vaccines against H5N1 avian influenza and other viruses.
Stem Cell Innovations (SCLL.PK) is a develop-stage company focused on its C3A human liver cell line for the production of human serum proteins, including the clotting factors, Factor VIII and Factor IX, used by hemophiliacs to allow their blood to clot.
Isolagen (ILE) develops products for skin and tissue rejuvenation which are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne, and burn scars using a patient's own (autologous) fibroblast cells produced by its Isolagen Process for therapeutic and cosmetic medicine applications.
CellCyte Genetics (CCYG.OB) is a development-stage company focused on cell expansion and cell maintenance through the use of its patented bioreactor technology. The Company's therapeutic focus is on investigative collaborations to research and develop compounds to allow the safe and efficient non-invasive delivery of stem cells through the patient's own circulatory system to a diseased or damaged organ.
Cryo-Cell (CCEL.OB) offers cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood stem cells as a family cord blood stem cell bank and preserves the specimens in commercially available cryogenic storage equipment.
Brainstorm Cell Therapeutics (BCLI.OB) is a development-stage company focused on focused on using a patient's own bone marrow stem cells to generate neuron-like cells that provide treatment for Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS) and spinal cord injuries.
Opexa Therapeutics (OPXA) develops autologous (patient-derived) cell-based therapies to treat multiple sclerosis (MS), rheumatoid arthritis (RA), and diabetes based on the Company's T-cell and adult stem cell technologies. Opexa's lead product candidate is Tovaxin (a T-cell based therapeutic vaccine) for MS which is in a Phase 2b clinical trial.
Neostem (NBS) operates a commercial, autologous (patient-derived) adult stem cell bank for the pre-disease collection, processing and long-term storage of stem cells from adult donors that they can access for their own future medical treatment. The Company manages a network of adult stem cell collection centers throughout the U.S. and conducts research to identify and isolate rare stem cells from bone marrow.
Bio-Matrix Scientific Group (BMSN.OB) is a provider of disposable instruments and medical devices which are used in stem cell extraction and tissue transfer procedures and also operates cryogenic stem cell banking facilities.
Stem Cell Therapeutics (Canada: SSS.V) is a regenerative medicine company that seeks to use drug-based treatments to stimulate a patient's existing stem cells in order to treat a variety of neurological conditions. The Company's pipeline includes lead compound NTx-265 for acute stroke, NTx-428 for traumatic brain injury, and NTx-488 for multiple sclerosis.
SCLL .10 friday
cb
WALL STREET JOURNAL ON STEM CELLS ( FEB.28 YH ) on WSJ , Page A4 :
" Democrats on Capitol Hill are also pushing items on their longtime Agenda , such as giving the District of Columbia a vote in Congress , " EXPANDING FUNDING FOR STEM-CELL RESEARCH " , and requiring broader use of renewable energy .
nice
cb
to many short shares, short covering, soon
cb
sorry !!!
Stem Cell on CNBC today ...
http://www.cnbc.com/id/15840232?video=1037584421&play=1
yes, time for a run SCLL
cb
Hadassah urges action on stem cells
February 8, 2009
WASHINGTON (JTA) -- A pro-stem cell research coalition which includes Hadassah urged President Obama to act quickly on the issue.
In a letter to the president, the Coalition for the Advancement of Medical Research said it was encouraged by a media report that Obama told a member of Congress it was a "guarantee" he would sign an executive order to lift the current federal restrictions on the funding of embryonic stem-cell research. But they were concerned that Obama also said he wanted to coordinate the order with legislation.
"We strongly urge you to issue a straightforward Executive Order that simply reverses President Bush's policy and calls on the National Institutes of Health to issue appropriate guidelines," the letter reads. "Follow-on legislation that codifies an Executive Order may be appropriate but, in the interest of timing and clarity of policy, the two do not need to be linked."
While Obama has not even been in the White House for three full weeks, Hadassah Washington Action office director Marla Gilson said that with all the "competing interests" for the president's time, there's a concern that this issue could get lost.
The letter is some "friendly encouragement," she said. "We think this is an easy one."
Gilson noted that since an executive order can be rescinded by another president, passing congressional legislation is important. But with Congress focused on the economy at the present time, it is not clear when such a bill could be passed and does not need to accompany the order.
"The longer we wait, the more people suffer," she said.
The Coalition for the Advancement of Medical Research includes more than 100 patient organizations, universities, scientific societies and foundations.
Scientists ready to jump-start embryonic stem-cell research
Saturday, February 7, 2009 5:41 PM
By Kevin Mayhood
THE COLUMBUS DISPATCH
Scientists in Ohio and across the country say they are eager to jump-start embryonic stem-cell research curtailed by the Bush administration.
President Barack Obama has promised to lift funding restrictions on the controversial studies, possibly as early this month.
"It's time to pursue embryonic stem-cell research," said Stanton Gerson, director of the Center for Stem Cell and Regenerative Medicine in Cleveland. "There's a huge amount of science to be done."
Embryonic stem cells can develop into any of the 220 specialized human cells. Scientists hope to use the cells for a host of diseases and disorders, from burn wounds and damaged blood vessels to leukemia and diabetes.
"There are a lot of scientific breakthroughs on the horizon ," said Chandan Sen, associate dean for translational and applied research at the Ohio State University College of Medicine.
"First and foremost, the playing field has not been level, nationally or globally. This would be huge for the nation our science would be empowered to compete."
Scientists say they are ready to submit grant proposals to study hundreds of cell lines developed using private money. They have been off-limits in federally funded research.
Chris Coburn, who runs the capital venture arm of the Cleveland Clinic, said Bush's restrictions had a "chilling effect" on private-research investments.
"If they lift the restrictions we will see an acceleration in development of stem-cell applications and medical products."
Two weeks ago, a California company became the first to receive federal approval to use a treatment derived from embryonic stem-cell research in a clinical trial - 10 years after the cells were first isolated.
The political debate over embryonic stem cells dates to 2001, when President George W. Bush agreed to allow the use of federal funds for research, but limited support to existing cell lines, which numbered 22.
Most were in far-from-ideal condition and unsuitable for clinical work.
Scientists remove stem cells from excess embryos that would be thrown away by fertility clinics.
Opponents say that killing any embryo for cells equates to abortion and argue that so-called adult stem cells should be used instead.
"Whether the (adult) stem cells can mimic embryonic stem cells impeccably is the question," said Eli Y. Adashi, an endocrinologist at Brown University and a member of the National Academy of Science Human Embryonic Stem Cell Research Advisory Committee.
To find out, "We need the reference point, the real McCoy."
Research was slowed here by a ban in Ohio as well.
While California, Maryland, Massachusetts and New York used state dollars to invest hundreds of millions of dollars in embryonic studies, former Ohio Gov. Bob Taft banned state funding.
Ohio has yet to fund embryonic stem-cell research, said Kelly Schlissberg, a spokeswoman for the Department of Development.
The Center for Stem Cell and Regenerative Medicine in Cleveland has been studying adult stem cells, with state funding, since 2003.
At Nationwide Children's Hospital, Brian K. Kaspar is studying the basic biology of stem cells. He is using one of the approved lines to study such things as spinal-cord damage and Lou Gehrig's disease.
Kaspar said he expects discoveries will come faster as more cell lines become available.
"Each line has different advantages."
kmayhood@dispatch.com
Obama to Restore Funding for Embryonic Stem Cell Research
Laura Robertson
February 6, 2009
It hasn't been the best couple of political weeks for religious conservatives, and the proverbial "light at the end of the tunnel" for them doesn't seem to be emerging any time soon.
They watched with sadness as President Obama revoked the Mexico City Policy, which provided taxpayer dollars to fund overseas family planning and abortion. While the family planning provisions were removed from the House version of the economic stimulus package, the clause preventing federal funding for religious buildings used for "sectarian purposes" remains in the Senate bill.
As if this weren't enough, the president is expected to restore federal funding to embryonic stem cell research.
At last night's House leadership retreat, the president told one congressman, "I guarantee you that we will sign an executive order for stem cells," but wants to work through the bill with the House and Senate. He said that "God gave us power to make smart decisions, to cure diseases, to alleviate suffering," and considers embryonic stem cell research as a way to achieve those goals.